Page last updated: 2024-10-30

mechlorethamine and Epstein-Barr Virus Infections

mechlorethamine has been researched along with Epstein-Barr Virus Infections in 3 studies

nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.

Epstein-Barr Virus Infections: Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Griffin, BE1
Kanakry, JA1
Li, H1
Gellert, LL1
Lemas, MV1
Hsieh, WS1
Hong, F1
Tan, KL1
Gascoyne, RD1
Gordon, LI1
Fisher, RI1
Bartlett, NL1
Stiff, P1
Cheson, BD1
Advani, R1
Miller, TP1
Kahl, BS1
Horning, SJ1
Ambinder, RF1
Tirelli, U1
Vaccher, E1
Spina, M1
Carbone, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease[NCT00003389]Phase 3854 participants (Actual)Interventional1999-06-17Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

5-year Overall Survival

Overall survival is defined as the time from randomization to death or last known alive. The 5-year survival rate is the probability a patient survives 5 years. (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5, and yearly for 5 years

InterventionProportion of patients (Number)
Arm A (ABVD)0.88
Arm B (Stanford V)0.88

Failure-free Survival at 5 Years

"Failure-free survival is defined as the time from randomization to the earlier of progression/relapse or death. The 5-year failure-free survival is the probability a patient is failure-free and survives 5 years.~Progression is defined as an increase in size of 25% of the sum of the products of the pretreatment measurements or appearance of new lesions. Significant enlargement of the liver or spleen is evidence of progression. A significant increase in size is defined as > 2.0 cm in distance between costal margin and the inferior margin of either organ.~Relapse is defined as the re-appearance of any clinical evidence of Hodgkin's disease in a patient who has had a complete response. Relapse for partial responders is defined as progressive disease relative to disease status during the partial remission." (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5

InterventionProportion of patients (Number)
Arm A (ABVD)0.74
Arm B (Stanford V)0.71

Incidence of Second Cancers

Number of patients who developed second primary cancers (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5, and yearly for 5 years

Interventionparticipants (Number)
Arm A (ABVD)15
Arm B (Stanford V)19

Reviews

1 review available for mechlorethamine and Epstein-Barr Virus Infections

ArticleYear
Hodgkin's disease: clinical presentation and treatment.
    Cancer treatment and research, 2001, Volume: 104

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined

2001

Trials

1 trial available for mechlorethamine and Epstein-Barr Virus Infections

ArticleYear
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.
    Blood, 2013, May-02, Volume: 121, Issue:18

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci

2013

Other Studies

1 other study available for mechlorethamine and Epstein-Barr Virus Infections

ArticleYear
[Nasopharyngeal carcinoma in sub-Saharan Africa: a tribute to Mr. Peter Clifford].
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:8

    Topics: Africa South of the Sahara; Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Epstein-Barr Virus

2009